huCD16A(FCGR3A) Mouse
Product Name
huCD16A(FCGR3A) Mouse
Product ID
C002019
Strain Name
C57BL/6NCya-Fcgr4tm1(hFCGR3A)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “huCD16A(FCGR3A) Mouse (Catalog C002019) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
FCGR3A
Gene Alias
CD16, FCG3, CD16A, FCGR3, IGFR3, IMD20, FCR-10, FCRIII, CD16-II, FCGRIII, FCRIIIA, FcGRIIIA
NCBI ID
Chromosome
Chr 1 (Human)
MGI ID
Datasheet
Strain Description
The FCGR3A gene (commonly known as CD16A) encodes the FcγRIIIA protein, a transmembrane receptor that binds the Fc portion of IgG with high functional affinity (particularly to immune complexes). This gene is primarily expressed in immune cells, most notably on Natural Killer (NK) cells, where it serves as a critical trigger for antibody-dependent cellular cytotoxicity (ADCC), as well as on subsets of monocytes and macrophages [1]. By binding to the Fc region of antibodies that have coated a target cell (such as a pathogen or tumor cell), the CD16A protein initiates intracellular signaling cascades that lead to the release of cytotoxic granules and pro-inflammatory cytokines [2]. While humans utilize FCGR3A, the mouse Fcgr4 gene serves as its functional ortholog, encoding the FcγRIV receptor that is essential for mediating similar IgG2-dependent effector functions in murine models [3]. In clinical contexts, polymorphisms in FCGR3A (such as the V158F variant) are significant because they influence the binding affinity for therapeutic antibodies, impacting the efficacy of monoclonal antibody treatments in oncology and autoimmune disorders [4]. Furthermore, dysregulation or mutations in this gene are associated with increased susceptibility to recurrent viral infections and systemic lupus erythematosus (SLE).
The huCD16A(FCGR3A) mouse model was generated by replacing the sequences from upstream of exon 1 to downstream of exon 5 of mouse Fcgr4 gene with the sequences from upstream of exon 1 to downstream of exon 6 of the human FCGR3A gene. This model is suitable for the study of various autoimmune diseases, such as systemic lupus erythematosus (SLE), as well as for oncology research, and for the screening, development, and safety evaluation of CD16A-targeted drugs.
Reference
Li W, Yang H, Dimitrov DS. Identification of high-affinity anti-CD16A allotype-independent human antibody domains. Exp Mol Pathol. 2016 Oct;101(2):281-289.
Wu J, Mishra HK, Walcheck B. Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy. J Leukoc Biol. 2019 Jun;105(6):1297-1303.
Lejeune J, Brachet G, Watier H. Evolutionary Story of the Low/Medium-Affinity IgG Fc Receptor Gene Cluster. Front Immunol. 2019 Jun 6;10:1297.
Abdel-Wahed MA, Sabbour GS, Hamed AI, El Kady MS, Mohammed SK, Shaaban MAAM. FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients. Sci Rep. 2024 Oct 29;14(1):26037.
Strain Strategy
The sequences from upstream of the exon 1 to downstream of the exon 5 of the mouse Fcgr4 gene were replaced with the sequences from upstream of the exon 1 to downstream of the exon 6 of the human FCGR3A gene.
Figure 1. Gene editing strategy for huCD16A(FCGR3A) mice.
Application Area
Screening, development, and preclinical evaluation of CD16A-targeted drugs;
Research on the pathological mechanisms and treatment methods of various autoimmune diseases, such as systemic lupus erythematosus (SLE);
Research on the pathological mechanisms and treatment methods of cancers.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
